[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intrabony-periodontal-defect\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intrabony-periodontal-defect":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,75,100,131,159,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100505212","clinical-effectiveness-of-biologic-agents-as-an-adjunct-to-non-surgical-periodontal-therapy-of-intrabony-defects-100505212",false,"NCT05858411","Clinical Effectiveness of Biologic Agents as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects","Evaluation of the Efficacy of rhPDGF, L-PRF and EMD as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with a diagnosis of periodontitis stage III or IV (grades A to C),\n* non-smokers or former smokers who quit at least 1 year ago, and\n* had not received any periodontal treatment in the 3 months prior to recruitment;\n* Presence of at least 1 Infrabony defect (PPD ≥ 5 mm with infrabony defect depth of ≥3mm at screening radiograph);\n* One and two wall infrabony defects at screening radiograph and periodontal charting.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of uncontrolled systemic diseases that could affect treatment outcomes such as diabetes mellitus with an HbA1C\\>7%, rheumatoid arthritis or any form of immunosuppression;\n* Subjects requiring antibiotic prophylaxis;\n* 3-wall infrabony defects;\n* Patients that had received systemic or local delivery of antibiotic therapy 6 weeks before enrollment;\n* Presence of furcation defect;\n* Chronic intake of NSAIDs or steroids, currently;\n* Patients undergoing orthodontic treatment, having removable prosthetic appliances, pregnancy, tumors of the oral cavity or the presence of any psychiatric condition that could affect participation.","ALL","18 Years",{"count":19,"type":20},88,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of the present study is to clinically and radiographically compare the efficacy of recombinant human platelet-derived growth factor (rhPDGF), Leukocyte-Platelet Rich Fibrin (L-PRF) and Enamel Matrix Derivatives (EMD) in intrabony defects following minimally invasive non surgical peridoontal therapy (MINST).\n\nThis study will be designed as a randomized clinical trial of 12-month duration. A total of 88 patients (each with a single infrabony defect) will be recruited and randomly equally distributed into 4 groups: an experimental group treated with MINST and rhPDGF, a second group treated with MINST + L-PRF, a third group treated with MINST and EMD and and a control group treated with MINST alone.\n\nEach defect will be treated with an ultrasonic scaler with dedicated thin tips for supra- and subgingival debridement associated with hand instrumentation under local anesthesia. Caution will be taken to preserve the stability of soft tissues. Following MINST experimental and control sites will be randomly chosen. The test sites will be treated by inserting a collagen plug soaked for at least 15 minutes in a 1.5cc solution containing hPDGF-BB. In the second group the infrabony defects will be treated with MINST and L-PRF. In the third group the infrabony defects will be treated with MINST and EMD. The control group will be treated with MINST alone.\n\nPre- and post-treatment clinical measurements were performed by an examiner blinded to the treatment modalities using a graded periodontal probe (HuFriedy UNC 15). Before the treatment and at 6 and 12 months post-treatment, all patients were examined by measuring the clinical attachment level, probing depth, gingival recession, full-mouth plaque score and bleeding on probing.\n\nStandardized radiographs of selected study sites will be taken at baseline and at the 6 and 12 months follow-up visits using the long-cone technique with a customized holder and a thermoplastic occlusal reference to allow reproducible positioning. All radiographs will be analysed by a dedicated dental software (Carestream Dental LLC Atlanta, GA, USA) to make linear measurements. The defect bone level (DBL), the defect angle (DA), the intra- and suprabony components of the defect and the radiographic defect area (RDA) will be evaluated.",[26,27,28,29],"Periodontal Diseases","Periodontal Attachment Loss","Pocket, Periodontal","Intrabony Periodontal Defect",[31,32,33,34,35],"rhPDGF","Growth factors","Periodontal regeneration","L-PRF","Enamel Matrix Derivatives","RECRUITING","2026-05-25",{"date":39,"type":40},"2026-05-28","ACTUAL",{"date":42,"type":40},"2023-01-08",{"date":44,"type":20},"2027-09-01",{"name":46,"class":47},"G. d'Annunzio University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100575141","comparison-of-mist-with-prf-and-gbt-with-prf-in-the-treatment-of-intrabony-periodontal-defect-a-prospective-rct-100575141","NCT06768424","Comparison of MIST With PRF and GBT With PRF in the Treatment of Intrabony Periodontal Defect. A Prospective RCT","Comparison of Minimally Invasive Surgical Therapy in Combination With Platelet Rich Fibrine and Guided Biofilm Therapy Combined With Platelet Rich Fibrine in the Treatment of Solitaire Intrabony Periodontal Defect A Prospective RCT.","Inclusion Criteria:\n\n* solitaire intrabony periodontal defect at least 4 mm\n\nExclusion Criteria:\n\n* Periodontitis with intrabony defect (Intrabony component ≥ 4mm, defect radiological angulation \\> 25°,\n* The patient is able to comply with the study -related procedures (i.e. good level of oral hygiene, follow-up procedures).\n* Patients must not be heavy smokers (\\\u003C5 cigarettes\u002Fday).\n* furcation involvement\n* Full mouth plaque and bleeding scores (FMPS and FMBS) of \\\u003C15% (O'Leary et al. 1972).\n* The patient is able to fully understand the nature of the study, signed informed consent.",true,"65 Years",{"count":59,"type":20},36,[23],"The aim is to evaluate in a prospective, randomized, controlled clinical study the healing of a MIST procedure combined with PRF, or GBT combined with PRF. Clinical, radiological evaluation of the regenerative surgical method and the GBT non-surgical therapy in solitaire deep intrabony periodontal defect.",[29],[64,65],"Guided biofilm terapy","Platelet Rich Fibrine","2026-04-25",{"date":68,"type":40},"2026-04-28",{"date":70,"type":40},"2023-12-20",{"date":72,"type":20},"2027-12-20",{"name":74,"class":47},"Semmelweis University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":48},"100473218","phase-1-rh-pdgf-vs-emd-for-treatment-of-intra-bony-defects-100473218","NCT05442034","Rh-PDGF vs EMD for Treatment of Intra-bony Defects","Rh-PDGF Versus Emdogain for Treatment of Intra-bony Defects","Inclusion Criteria:\n\n* Age is 18 years old and older\n* Absence of relevant medical conditions\n* Availability for 6-month follow-up\n* Subjects who recently have received scaling and root planing due to periodontal disease\n* Single-rooted and multi-rooted teeth in either the maxilla or the mandible.\n* Presence of interdental periodontal pocket with PD ≥ 6 mm associated to an intra-bony component ranged from 3 to 6 mm.\n* Non-contained intra-bony defects (1-wall, 2-wall intra-bony defects)\n* Full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) \\\u003C20% at surgery\n\nExclusion Criteria:\n\n* Female patients who are pregnant or planning to be pregnant during the period of the study\n* Heavy smokers (\\>10 cigarettes a day)\n* Subjects not willing to comply to the study protocol\n* Patients with uncontrolled diabetes (HbA1c \\>7.5)\n* Patients receiving medications that may affect periodontal status in the previous 6 months (e.g., Phenytoin, Alendronate)\n* Periapical lesion in the tested sites",{"count":59,"type":20},[84,85],"PHASE1","PHASE2","Treatment of intra-bony defects is challenging and requires extensive knowledge of the etiology, anatomy, occlusion, and available biomaterials that can be used to treat this kind of defects. Patients who received scaling and root planing at the college of dental medicine due to periodontal disease, will be screened for inclusion. Only subjects who showed persistent deep probing depth associated with an intrabony defect will be included and will be randomly allocated to one of two treatment groups. One group will be treated using recombinant human platelet derived growth factor (GEM-21) (test) added to allogenic bone graft, second group will be treated using enamel matrix derivatives (EMD) (control) with allograft. Both groups will be treated using the same surgical protocol. Patients will be followed up for a period of 6 months and 12 months, before getting re-evaluated for assessing the effectiveness of the applied therapies.",[29],[33,89,90],"Inta-bony defects","Enamel matrix derivatives","2026-04-13",{"date":93,"type":40},"2026-04-16",{"date":95,"type":40},"2023-01-01",{"date":97,"type":20},"2027-06-30",{"name":99,"class":47},"Nova Southeastern University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":48},"100604227","treatment-of-intrabony-defects-with-injectable-platelet-rich-fibrin-and-xenogenic-grafts-100604227","NCT07146776","Treatment of Intrabony Defects With Injectable Platelet-Rich Fibrin and Xenogenic Grafts","Evaluation of the Effect of Injectable Platelet-Rich Fibrin in the Treatment of Periodontal Intrabony Defects With Xenogenic Grafts: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Male and female patients aged 18-65 years\n* Patients with Stage III Periodontitis according to the AAP-EFP 2017 Periodontal Disease Classification\n* PPD≥5 mm (if persistent 6 weeks after initial periodontal treatment)\n* Intrabony defects in the interproximal region with 2 or 3 walls and a depth of at least ≥3 mm\n* Non-smokers (those who smoke up to 10 per day may be included)\n\nExclusion Criteria:\n\n* Patients under 18 years of age or older than 65 years of age\n* Patients unable to consent\n* Systemic diseases that could affect the success of surgery, such as uncontrolled diabetes\n* Single-walled intrabony defects\n* Those who have taken antibiotics, anti-inflammatory or immunosuppressive drugs, or birth control pills within the three months prior to the study\n* Those who have received active periodontal treatment within the last six months and periodontal surgery within the last year\n* Smoking more than 10 cigarettes per day\n* Pregnancy or breastfeeding\n* Those taking medications that affect the gums (e.g., calcium channel blockers, phenytoin or cyclosporine)\n* Teeth with furcation defects\n* Those undergoing active orthodontic treatment\n* Those who are allergic to the biomaterials used in the study or prescribed medications",{"count":108,"type":20},16,[23],"The use of injectable platelet-rich fibrin (i-PRF) in both surgical and non-surgical dental treatments has become increasingly widespread. Hard tissue grafts can produce \"sticky bone,\" and bone gain can have a positive effect on intrabony defects frequently seen in periodontal disease, compared to grafts alone. This study aims to clinically and radiographically evaluate the effectiveness of using bovine-derived xenogenic bone grafts in combination with i-PRF and bovine-derived xenogeneic bone grafts alone in patients with intrabony defects and stage III periodontitis.",[112,29,26,113,114],"Periodontitis","Periodontal Defect","Periodontal Bone Loss",[116,117,118,119,120,121],"i-prf","injectable prf","injectable platelet rich fibrin","xenogenic graft","xenogenic bone graft","xenograft","2025-08-31",{"date":124,"type":40},"2025-09-08",{"date":126,"type":40},"2025-07-12",{"date":128,"type":20},"2026-07-01",{"name":130,"class":47},"Saglik Bilimleri Universitesi",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":48},"100519783","phase-4-evaluation-of-autogenous-demineralized-dentin-graft-vs-autogenous-bone-graft-in-management-of-intrabony-defects-100519783","NCT06048042","Evaluation of Autogenous Demineralized Dentin Graft Vs Autogenous Bone Graft in Management of Intrabony Defects","Clinical and Radiographic Evaluation of Autogenous Demineralized Dentin Graft Versus Autogenous Bone Graft in Management of Periodontal Intrabony Defects Using Modified Minimally Invasive Surgical Technique: A Non-Randomized Clinical Trial","Inclusion Criteria:\n\n* Patient-related criteria:\n\n  * Motivated patient 18 years of age or order.\n  * Patient consulting in the outpatient clinic.\n  * Patient ready to perform oral hygiene instructions.\n  * Provide informed consent.\n  * Accepts the 6 months follow-up period.\n* Teeth related criteria:\n\n  * Tooth with two or three-walled intra-bony defect, probing depth ≥ 5mm with intra osseous defect ≥ 3mm.\n  * Mature permanent tooth.\n  * Unrestorable tooth or fractured tooth beyond restoration, impacted third molar or supernumerary tooth to be extracted and used as whole tooth graft inside the intrabony defect.\n\nExclusion Criteria:\n\n* Patient-related criteria:\n\n  * Medically compromised patients.\n  * Pregnant women.\n  * Uncooperative patients.\n  * Smokers.\n  * Systemic diseases that may compromise healing or bone metabolism (e.g diabetes, hyperthyroidism).\n  * Failure to maintain good oral hygiene.\n* Teeth related criteria:\n\n  * Teeth with supra-bony defects.\n  * Teeth with grade III mobility.\n  * Teeth having interproximal craters, grade III furcation involvement, and grade III mobility.\n  * Presence of caries or overhanging restorations.\n  * Presence of peri-apical injuries.","50 Years",{"count":140,"type":20},24,[142],"PHASE4","The main goal is to evaluate and compare the clinical and radiographic efficacy of autogenous demineralized dentin as bone graft substitute versus autogenous bone graft when performed with modified minimally invasive surgical technique (M-MIST) in the treatment of periodontal intrabony defects.\n\nThe main question is: In periodontitis patients with intrabony defects, will using autogenous demineralized dentin as bone graft substitute result in clinical attachment gain and linear bone fill similar to autogenous bone graft following modified minimally invasive surgical technique? After enrolment, each participant with intra-bony defects will receive the initial phase of the therapy, which will include oral hygiene instructions, supragingival and subgingival debridement using ultrasonic and hand instrumentations and relieving of occlusal trauma if any.\n\nAfter 4-6 weeks, an individually customized positioning stent will be fabricated for each participant and a pre-operative periapical x-ray using parallel-angle technique will be employed using X-ray film holding system to ensure accuracy and reproducibility of the measurements.\n\nCriteria used to indicate that surgery is required include the persistence of interproximal defect with PD (Probing depth) ≥ 5 mm, CAL (Clinical attachment loss) ≥ 4 mm.\n\nSurgical procedures will include flap elevation for approaching the defect-associated sites using the modified minimally invasive surgical technique (M-MIST).\n\nIntervention group: The defect will be filled with autogenous demineralized dentin graft prepared from the participant's freshly extracted own teeth.\n\nControl group: The defect will be filled with autogenous bone graft harvested from the retromolar area.\n\nFor both groups, flaps will be approximated and sutured at the original position. All the subjects will be evaluated at 1, 3, and 6 months for clinical and radiographic parameters. Outcomes:The results of Clinical attachment level (CAL) gain, Linear bone fill, Gingival index (GI), Plaque index (PI), Probing pocket depth (PPD), Gingival recession (GR), Bleeding on probing (BoP), Postoperative pain and Patient satisfaction will be measured at baseline, 1 month, 3 months and after 6 months.",[29],[29,146,147,148,149],"Demineralized dentin graft","Autogenous bone graft","modified minimally invasive surgical technique","M-MIST","2024-08-23",{"date":152,"type":40},"2024-08-26",{"date":154,"type":40},"2024-07-17",{"date":156,"type":20},"2025-03",{"name":158,"class":47},"Cairo University",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":177,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100538956","clinical-evaluation-of-injectable-alb-prf-in-the-management-of-intrabony-defect-in-stage-iii-periodontitis-patients-100538956","NCT06297577","Clinical Evaluation of Injectable Alb-PRF in the Management of Intrabony Defect in Stage-III Periodontitis Patients","Clinical Evaluation of Injectable Albumin Platelet Rich Fibrin (Alb-PRF) Versus Minimally Invasive Surgical Technique (MIST) in the Management of Intra-bony Defect in Stage-III Periodontitis Patients. A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Stage III periodontitis patient having at least one tooth with 2-wall, 3-wall, or combined 2- to 3-wall intrabony defect ≥3 mm in depth (assessed by bone sounding, radiographic examination) with clinical attachment level (CAL) ≥5mm and probing pocket depth (PPD) ≥6 mm with no defect extending to a root furcation area.\n2. Vital teeth.\n3. No history of intake of antibiotics or other medications affecting the periodontium in the previous 6 months.\n4. No periodontal therapy carried out in the past 6 months.\n5. Ability to sign an informed consent form.\n6. Patients age ≥18 years old.\n7. Patients who are cooperative, motivated, and hygiene conscious.\n8. Systemically free according to Cornell Medical Index.\n\nExclusion Criteria:\n\n1. Patient undergoing orthodontic treatment.\n2. Pregnant females or breast feeding.\n3. Smokers.\n4. Teeth mobility greater than grade I.","60 Years",{"count":168,"type":20},32,[23],"Clinical Evaluation of Injectable Albumin Platelet Rich Fibrin Versus Platelet Rich Fibrin in the Management of Intra-bony Defect in Stage-III Periodontitis Patients.\n\nThe goal of this clinical trial is to compare Injectable Albumin Platelet Rich Fibrin Versus Platelet Rich Fibrin in the Management of Intra-bony Defect in Stage-III Periodontitis Patients. The main question aims to answer are:\n\nwill Albumin Platelet Rich Fibrin (Alb-PRF) as adjunct to minimally invasive surgical technique (MIST) be superior in terms of improvement in clinical parameters compared to the use of PRF with MIST.",[29],[173,174,175,176],"Albumin Platelet Rich Fibrin (Alb-PRF)","Minimally Invasive Surgical Technique (MIST)","Stage 3 periodontitis","Intrabony defect","NOT_YET_RECRUITING","2024-08-06",{"date":180,"type":40},"2024-08-07",{"date":182,"type":20},"2024-08-30",{"date":184,"type":20},"2025-10-30",{"name":158,"class":47},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":177,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":4},"100556829","simplified-papilla-preservation-flapsppf-and-enamel-matrix-derivativeemd-with-or-without-connective-tissuectg-wall-for-the-treatment-of-non-contained-infrabony-defects-a-randomized-controlled-clinical-trail-100556829","NCT06530199","Simplified Papilla Preservation Flap(SPPF) and Enamel Matrix Derivative(EMD) With or Without Connective Tissue(CTG) Wall for the Treatment of Non Contained Infrabony Defects. A Randomized Controlled Clinical Trail","Inclusion Criteria:\n\n* Patients willing to participate in the study.\n* Participants aged ≥18 years to 55 years.\n* Presented with non contained infra bony defects.\n* Presence of at least 1 non contained infra bony defect(IBD) with a pocket probing depth ≥6mm after reevaluation of the hygienic phase and a depth of IBD ≥3mm as detected on radiographs, with radiographic angulation of ≥37⸰ , and exhibiting a 1 or 2 wall infra bony defect15(assessed by a bone sounding and confirmed intrasurgically)\n* Patient's full mouth plaque score and bleeding score \\\u003C20% at the time of surgical procedure.\n* No history of periodontal surgery at the experimental site.\n\nExclusion Criteria:\n\n* Grade III mobility, endodontically treated teeth.\n* Pregnant and lactating females.\n* History of tobacco smoking .\n* Patients with systemic disease.\n* Known allergy or hypersensitivity to EMD.\n* Presence of pulpal and peri apical involvement","55 Years",{"count":194,"type":20},30,[23],"Research is to compare and evaluate the clinical and radiographic outcomes of the enamel matrix derivative with or without connective tissue wall graft for noncontained infrabony defects using simplified papilla preservation technique .",[29],"2024-07-27",{"date":200,"type":40},"2024-07-31",{"date":202,"type":20},"2024-07",{"date":204,"type":20},"2025-07",{"name":206,"class":47},"Krishnadevaraya College of Dental Sciences & Hospital"]